Merrimack (MACK) Buy Rating Reiterated at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Merrimack Pharma (MACK) Rips Higher on Baxter (BAX) Agreement
September 24, 2014 8:12 AM EDTMerrimack Pharmaceuticals (Nasdaq: MACK) shares are ripping in early trading following news that the company entered an exclusive agreement with Baxter International Inc. (NYSE: BAX).
According to an... More
Merrimack Pharma (MACK), Baxter (BAX) Enter Exclusive Agreement Covering MM-398
September 24, 2014 7:01 AM EDTBaxter International Inc. (NYSE: BAX) and Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as ''nal-IRI.'' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan, and Merrimack retains commercialization rights in the United States; the rights in Taiwan are held separately.
MM-398 is an investigational drug candidate for which Merrimack is preparing a New Drug Application in the United... More
